🍼 Can Abbott’s Formula Troubles End?

Stitch fix shares tank premarket.

Hey Global Investor! Here’s what you need to know before the US markets open.

Market Snapshot 📈

S&P 500 (Thursday’s Close) 4,017.82 -97.95 (2.38%)

NASDAQ (Thursday’s Close) 11,754.23 -332.04 (2.75%)

FTSE 100 (4:30 PM IST) 7,388.60 -87.60 (1.17%)

NIFTY 50 (Today’s Close) 16,201.80 -276.30 (1.68%)

USDINR (4:30 PM IST) 77.84 (1 Year +6.65%)

🔥 Top Movers

GLSI +23.47%
BMEA +15.79%
BEEM +14.23%

SATL -24.21%
PAGS -23.80%
NRGV -21.49%

🍼 Abbott: Trouble In A Formula?

Abbott Laboratories (ABT), the largest baby formula manufacturer in the US, is in the eye of a storm. At the heart of the controversy is its unit in Sturgis, Michigan, which produces one-fifth of the total baby formula in the US. Can Abbott find a formula to end its troubles?

A Created Necessity

According to UNICEF, a vast majority of pregnant women and parents of infants were at the receiving end of targeted marketing from formula milk companies, violating international standards on infant feeding practices.

The report says formula milk marketing reached 84% of all women surveyed in the UK, 92% in Vietnam, and 97% in China. The global infant formula market is likely to double by 2030 to $125.2B, growing at an 8.75% CAGR.

Abbott ranks among the top healthcare companies globally. It successfully spun off its research-based pharma business into AbbVie in 2013. Over time, it has become the largest baby formula producer in the US.

Breast milk contains a probiotic named 2’-FL HMO (Human Milk Oligosaccharides). Abbott became the first company in the world to provide this substance in the two infant formulae – Similac Pro-Advanced and Similac Pro-Sensitive – launched in 2016. Abbott was awarded the Chicago Innovation Award in 2017 for one of the biggest breakthroughs in infant formulas in decades.

The infant formula market in the US has very high entry barriers owing to extremely tight regulations, thus leaving the market in the hands of a select few. Abbott’s Similac and Reckitt Benckiser Group’s Enfamil sold 80% of the infant and toddler formulae in 2021.

Most of the baby formula in the US is purchased through the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). The program, which is federally funded, but implemented by states, enables states to award exclusive sales contracts to a single formula manufacturer in exchange for discounts.

Such is Abbott’s domination in this market that it has contracts with 34 states for its product. Reckitt’s Enfamil comes a distant second with 10, while Nestle has contracts for six states. In 2021, Abbott’s infant formula, which falls under its Nutritional Products category, contributed to one-fifth or 20% of the overall topline. But there was more than what met the eye.

A Murky (Formula) Tale

As the pandemic began to cripple supply chains across the globe, baby formula began to disappear off the shelves. The severity of the issue only came to light when Abbott halted production at its facility in Sturgis, Michigan, in February this year. The factory produces one-fifth of the total baby formula in the US. It also issued a voluntary recall of products, causing further shortages.

Investigations by the US FDA found traces of a potentially deadly bacteria, raising the possibility that contaminated products from the plant caused illness in several infants. Abbott reached an agreement with the regulator in mid-May that it would address unsanitary conditions that led to the contamination. Production resumed four days later, on May 20, under intense regulatory scrutiny.

All hunky-dory again? Not really. It turns out Abbott had known about these issues much earlier than what was known to the public. A former Abbott employee filed a complaint in February 2021 under the Occupational Safety and Health Administration’s whistleblower-protection program. The same person escalated it to the FDA in October.

The complaint alleged bacteria contaminated the production process, and employees avoided disclosing information to the regulators. In addition, FDA chief Robert Califf termed the Abbot facility “egregiously unsanitary,” with bacteria growing at multiple sites, broken equipment, etc.

This wasn’t the first instance of the Sturgis facility being under the scanner. In 2010, Abbott recalled 5M containers of powdered Similac after discovering beetles or their larvae in them. Subsequent FDA inspections also detected damage to drying equipment, defects in formula cans’ seams, and standing water. An inspection in 2019 found Cronobacter in a batch of formula.

During the first week of May, 43% of baby formula supplies were out of stock at stores across the US. Abbott has restarted the production of Similac and EleCare, a formula for children who struggle to digest other products, along with other specialty and metabolic formulas. The products, though, will only reach the shelves by the end of the month.

Shares of Abbott are down 18% this year. Even then, it trades at a premium compared to its peers. On a trailing-12-month price-to-earnings basis, the stock trades at 27x, compared to Johnson & Johnson and Amgen, both of whom trade at 24x.

What impact the formula fiasco has on Abbott’s financials will be evident soon enough. For now, the company needs a formula to put an end to the issues it’s facing at the Sturgis facility!

Market Reaction
ABT ended at $112.71, down 1.67%.

Company Snapshot 📈

ABT $112.71 -1.98 (1.73%)

Analyst Ratings (22 Analysts) BUY 82%  HOLD 9%  SELL 9%

Newsworthy 📰

Coming Off: Stitch Fix shares sink after company announces layoffs, offers weak guidance (SFIX -14.01%) (Premarket)

Profit Concerns: DocuSign shares craters after first-quarter earnings miss (DOCU -26.68%) (Premarket)

Covid Impact: Nio reports wider first-quarter loss as Covid shutdowns in China hamper deliveries (NIO -7.65%)

Later Today 🕒

  • 6:00 PM IST: Consumer Price Index
  • 7:30 PM IST: Consumer Sentiment Index
  • 11:30 PM IST: Federal Budget Balance

Today’s Fun Fact

Disney held the patent for Technicolor for two years, making him the only animator allowed to make color animated films

Disclaimer: The content of this article has been created and published by Winvesta India Technologies Pvt. Ltd., in order to ease the reader’s understanding of the subject matter. The information and/or content (collectively “Information”) provided herein is general information sourced through various news reports and does not constitute a research report or a research analysis. The Information is not intended to offer advice, target or solicit any particular customer or group of customers to buy or sell securities. 

Winvesta does not render any research or advisory services and provides a more detailed description of its services on its website and mobile application along with the terms and conditions published therein from time to time. While reasonable care has been exercised to ensure that the Information is adequate and reliable, no representation is made by Winvesta as to its accuracy or completeness and Winvesta, its affiliates, subsidiaries and employees accept no liability of whatsoever nature for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this Information. Neither Winvesta nor any of its affiliates are acting as an investment adviser, research analyst or in any other fiduciary capacity. Accordingly, reader’s are expected to undertake their own due diligence in consultation with their own advisors and are advised not to solely rely on the Information. Any such reliance shall be at the reader’s own risk. 

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing.

Start Building Your Global Portfolio Today

Download Winvesta App now to Get Started